NCT06679257

Brief Summary

LTx has the shortest survival of all solid organ transplants. The complex and time-demanding diagnostics of allograft dysfunction are a significant reason for this. The current study aims overarchingly to improve survival after lung transplantation (LTx) through precise and fast diagnostics. The specific aim is to develop direct-to-clinical implementation biomarkers for the most important aspects of long-term survival after LTx. An in-house-developed PCR-based cell-free-DNA methodology (cf-DNA) will be used for allograft damage and combined with specific other biomarkers to identify damage type. The current clinical golden standard for damage identification will be performed at every sampling instance. The research will be a single-centre prospective observational cohort study. The control samples at all time points will consist of the samples without allograft damage. Blood will be drawn at fixed time points and clinical events. All analyses will be performed at a separate lab, blinded to the patient's status. .

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
146

participants targeted

Target at P50-P75 for all trials

Timeline
56mo left

Started Nov 2024

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress24%
Nov 2024Dec 2030

First Submitted

Initial submission to the registry

October 28, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 7, 2024

Completed
8 days until next milestone

Study Start

First participant enrolled

November 15, 2024

Completed
5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2029

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2030

Last Updated

September 16, 2025

Status Verified

September 1, 2025

Enrollment Period

5 years

First QC Date

October 28, 2024

Last Update Submit

September 15, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Damage distinction

    Null hypothesis: Levels of Cf-DNA is not different at samples taken with allograft damage and no allograft damage.

    One month, three months, one year, three years, five years

Secondary Outcomes (1)

  • Damage detection Limit

    One month, three months, one year, three years, five years

Study Arms (1)

Lung transplanted patients

All eligible patients were transplanted and followed up within the catchment area of the participating centre.

Diagnostic Test: cell-free dNA

Interventions

cell-free dNADIAGNOSTIC_TEST

Blood samples taker per protocol, analyses performed by a lab blinded to the status of the respective patients

Lung transplanted patients

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Newly lung transplanted patients within scandinavia

You may qualify if:

  • Luing Transplanted and followed up within the reach of the study paricipating centres.
  • A good understanding to read and write within the languages in which the consent is provided.

You may not qualify if:

  • Not Lung Transplanted or not followed up within the reach of the study paricipating centres.
  • No good understanding to read and write within the languages in which the consent is provided.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sahlgrenska University hospital

Gothenburg, Västra Götaland County, 413 45, Sweden

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Cell free DNA

MeSH Terms

Conditions

Rejection, Psychology

Interventions

Noninvasive Prenatal Testing

Condition Hierarchy (Ancestors)

Social BehaviorBehavior

Intervention Hierarchy (Ancestors)

Liquid BiopsyBiopsyCytodiagnosisCytological TechniquesClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisGenetic TestingSpecimen HandlingPrenatal DiagnosisDiagnostic Techniques, Obstetrical and GynecologicalInvestigative TechniquesGenetic TechniquesGenetic ServicesHealth ServicesHealth Care Facilities Workforce and ServicesDiagnostic ServicesPreventive Health Services

Central Study Contacts

Jesper M Magnusson, MD, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR INVESTIGATOR
PI Title
MD, PhD, Associate professor

Study Record Dates

First Submitted

October 28, 2024

First Posted

November 7, 2024

Study Start

November 15, 2024

Primary Completion (Estimated)

December 1, 2029

Study Completion (Estimated)

December 1, 2030

Last Updated

September 16, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will share

Locations